LETTER TO THE EDITOR

The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature

Letter — The article by Bulteel et al.,1 published in the September issue of the journal, has investigated the rate of M184V emergence in patients receiving HAART combinations containing efavirenz (EFV), tenofovir (TDF) and lamivudine (3 TC) or emtricitabine (FTC) within the UK Collaborative HIV Cohort. By analyzing 304 genotypic resistance tests, the authors asserted that, although patients receiving 3 TC-based regimens were more likely to develop M184V than those receiving FTC-based regimens (event rate: 0.55 [95%CI: 0.28–0.96] for 3 TC versus 0.34 [95%CI: 0.21–0.46] for FTC), this association was not statistically significant in both univariable and multivariable models. These results are different from those reported in previous studies from our and other groups2–4 showing a significant decrease in M184V emergence in patients failing FTC + TDF-based compared to 3 TC + TDF-based HAART (Table 1). The lower prevalence of M184V in FTC-containing regimen was also supported by a recently published letter showing a strong trend (P = 0.051) towards higher rates of resistance to the 3 TC containing regimen 5.5 (1.8–12.8) per 1000 patient years when compared with the FTC containing regimens 1.7 (0.8–3.2) per 1000 patient years.5

Such discrepancy in M184V prevalence can be explained by the profound differences in the dataset of patients analyzed. The most striking difference is represented by the fact that the studies by our and other groups2–4 have analyzed viremic patients at the time of starting a FTC + TDF-based or 3 TC + TDF-containing HAART. Conversely, Bulteel et al.1 have analyzed patients starting a first line FTC + TDF- or 3 TC + TDF-containing HAART. Conversely, Bulteel et al.1 have included only patients not at the first prescription of FTC/3 TC + TDF-based regimen. In a previous analysis presented at 16th CROI 2009 (abs#642), including also patients previously treated with 3 TC, Svircher et al. showed that a previous 3 TC exposure was an independent factor correlated with an increased rate of M184V detection in multivariate analysis (Odds Ratio [CI]: 2.28 [1.74–2.98], P = 0.001). This highlights the existence of a viral reservoirs enriched with the M184V mutation that can re-emerge despite FTC use. This is in line with a previous study showing that 3 TC-resistant HIV-1 variants can persist (as minority species) despite highly unfavorable conditions in vivo and in vitro.

Furthermore, the studies by our and other groups2–4 have included patients receiving as third drug either EFV or a Protease Inhibitor boosted with ritonavir (PI/r) (Table 1). Conversely, Bulteel et al.1 have included only patients receiving EFV as 3rd drug (Table 1). The protective role of PIs/r in delaying drug resistance emergence is well known. We showed that the use of a PI/r is an independent factor correlated with a lower M184V detection at virological failure.2,4 In addition, Gupta et al.6 (in a systematic review of clinical trials) showed that the prevalence of M184V was 35.3% in patients starting NNRTI-based HAART compared with 21.0% in those receiving PI/r.

Thus, based on the above-mentioned differences, it is likely that the criteria used by Bulteel et al.1 to select patients may not allow to extrapolate conclusive information on the rate of M184V emergence between 3 TC and FTC. It should be also noted that when Bulteel et al.1 focused on a subgroup of patients experiencing virological failure for the first time, the M184V prevalence was 13.5% for FTC + TDF + EFV treated patients and 22.6% for 3 TC + TDF + EFV treated ones (Table 1). While prevalence of M184V in patients failing FTC + TDF + EFV was nearly close to that observed by our studies,2,4 its relevance in 3 TC + TDF + EFV is much lower. Beyond the above-mentioned factors, it might be thought...
that the 3 TC-failures observed in Bulteel’s study could be due to the poor adherence resulting from high pill burden, adverse events, or long-term toxicity, and not by the selection of drug resistance. The lower M184V prevalence in patients failing FTC + TDF-based than 3 TC + TDF-based HAART relies on both basic and clinical bases. Indeed, it can be explained by the higher potency of FTC than 3 TC, and/or by the higher intracellular half-life of FTC triphosphate than 3 TC triphosphate due to FTC ability to inhibit the cellular efflux proteins. The higher potency and intracellular half-life of FTC triphosphate than 3 TC by the higher potency of FTC than 3 TC, and/or by the effects of drug resistance emergence. Their knowledge is mandatory for the achievement of long term virological success, thus improving the quality of life of patients and optimizing the costs related to public health.

References


Please cite this article in press as: Svicher V, et al., The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature, J Infect (2014), http://dx.doi.org/10.1016/j.jinf.2014.05.001


